Anocca is creating a pipeline of precision T-cell immunotherapies by combining its novel approach to T-cell biology, cutting-edge biotechnologies and integrated software.

Anocca

Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity.
 
Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. 
 
Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.

European Investment Bank

Swedbank Robur’s Ny Teknik

Nidoco

Ramsbury Invest AB

Harald Mix

Robert Andreen

Swedbank Robur

Mellby Gård AB

Michano

We’re kicking-off 2024 with exciting news! We are pleased to announce that Anocca has secured a GMP manufacturing license from the Swedish Medical Products Agency for our in-house #CellTherapy facility, the largest in the Nordics.

This key regulatory milestone reinforces our commitment to precision #immunotherapy and paves the way for clinical development of Anocca’s #KRAS #TCRT product franchise.

KRAS driver mutations are responsible for aggressive #cancer forms and TCR-T is a therapeutic modality with the potential to transform patient outcomes. 

Manufactured with a next-gen autologous approach, we're set to initiate clinical trials later this year in hard-to-treat solid tumour indications.

🔗Read the full press release here: https://lnkd.in/e5vp4SY3

Anocca is hiring - Are you our Corporate Business Controller?

We are seeking a highly motivated operational Business Controller to join our team. The role allows exposure to all key aspects of financial management and operations. The ideal candidate will have a proven track record of managing financial operations, performing financial analysis, and providing insights to senior management.

The Business Controller will work closely with Anocca’s CFO, Finance organisation and Senior Leadership team and will play a critical role in supporting the company in its transformation from a leading research to clinical stage organisation.

The role is full-time and located at our headquarters in Södertälje.

More information is here: https://lnkd.in/dzBvHW8

Meet our CEO Reagan Jarvis at the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024.

We’re open to #partnering and #investor meetings to discuss how our deep asset pipeline and novel technologies can help patients.

Anocca’s platform decodes the complexity of T cell biology and enables development of powerful engineered TCR-T #immunotherapies for hard-to-treat solid #tumour indications. 

📧: Schedule a meeting with us at #JPM2024: bd@anocca.com

#biotech #celltherapy #cellandgenetherapy

Our CDO, Mark Farmery will be delivering a key session at Cell & Gene Therapy Manufacturing & Commercialization Europe, from December 4 – 6 in Dublin, Ireland!

📅11:05 – 11:40 | December 5 | Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies

Learn how Anocca leverages its precision biology discovery platform and advanced in-house manufacturing capabilities to decode the complexity of the human immune system and encode and develop powerful engineered TCR-T cell #immunotherapies for hard-to-treat solid #cancer indications.

Connect with Mark there to discuss how we are preparing to take our first highly validated TCR-T product builds into clinical development using the partnering system: https://lnkd.in/ezGrMkME

🔗 Join #CellGene 2023: https://lnkd.in/eeWBzXk

Informa Connect Life Sciences

#biotech #celltherapy #cellandgenetherapy

COM:ANOCCA

Anocca

Financials Not Available